VARIPULSE Platform (VARIPULSE Catheter; TRUPULSE Generator; Sterile Interface Cable; nGEN Pump)
Biosense Webster, Inc. · Decision date Sep 10, 2026
What did the FDA decide?
The FDA database entry records a 30-day notice for supplement S019 to PMA P240006, submitted by Biosense Webster, Inc. The stated purpose is to implement a repackaging and relabeling operation for the VARIPULSE Platform, which includes the VARIPULSE Catheter, TRUPULSE Generator, Sterile Interface Cable, and nGEN Pump. The supplement type is a process change involving the manufacturer, sterilizer, packager, or supplier.
The decision field shows OK30, and the supplement reason is listed as a process change. The device category describes a percutaneous cardiac ablation catheter for treating atrial fibrillation with irreversible electroporation. The notice does not state that the device received a new approval or that safety or effectiveness was independently demonstrated. Specific details about the new packaging or labeling content are not provided in the source fields.
FDA approval order statement
to implement a repackaging and relabeling operation
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 10, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P240006/S019
- Regulatory pathway
- PMA supplement
- Applicant
- Biosense Webster, Inc.
- Product code
- QZI
- Decision code
- OK30
- Decision date
- Sep 10, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.
- Applicant
- Biosense Webster, Inc.
- Product code
- QZI
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240006. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240006 · Original PMA
VARIPULSE Platform (VARIPULSE Catheter; TRUPULSE Generator; Sterile Interface Cable; nGEN Pump)
P240006/S019 received
Application receipt date recorded by FDA.
P240006/S019 · FDA decision
30-Day Notice
P240006/S020 · Related supplement
VARIPULSE BI-DIRECTIONAL CATHETER
P240006/S018 · Related supplement
Varipulse Bi-Directional Catheter
Timeline entries are records held by MedtechLedger for P240006. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240006
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biosense Webster, Inc. | PMA approval | Nov 6, 2024 | FDA | |
VARIPULSE BI-DIRECTIONAL CATHETERP240006/S020 | Biosense Webster, Inc. | PMA supplement | Sep 15, 2026 | FDA |
Varipulse Bi-Directional CatheterP240006/S018 | Biosense Webster, Inc. | PMA supplement | Nov 3, 2026 | FDA |
Explore the linked device profile
Other records with product code QZI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Globe Catheter and Globe Pulsed Field SystemP240044/S007 | Kardium, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Globe Pulsed Field System; Globe CatheterP240044/S008 | Kardium, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Volt PFA SystemP250022/S002 | ABBOTT MEDICAL | PMA supplement | Oct 15, 2026 | FDA |
Affera Sphere-9 Mapping and Ablation CatheterP240013/S032 | Medtronic, Inc. | PMA supplement | Oct 9, 2026 | FDA |
Volt PFA Catheter, Sensor EnabledP250022/S009 | ABBOTT MEDICAL | PMA supplement | Oct 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biosense Webster, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 31 Technology Dr., Suite 200, Irvine, CA, 91618
Sources and methodology
- Original FDA record: P240006/S019
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
